Ignite Creation Date:
2025-12-24 @ 6:38 PM
Ignite Modification Date:
2026-02-24 @ 5:50 AM
Study NCT ID:
NCT01908257
Status:
COMPLETED
Last Update Posted:
2014-01-09
First Post:
2013-07-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lesinurad Interaction Study With Ranitidine
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000593471', 'term': 'lesinurad'}, {'id': 'D011899', 'term': 'Ranitidine'}], 'ancestors': [{'id': 'D005663', 'term': 'Furans'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 16}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-01', 'completionDateStruct': {'date': '2013-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-01-08', 'studyFirstSubmitDate': '2013-07-23', 'studyFirstSubmitQcDate': '2013-07-23', 'lastUpdatePostDateStruct': {'date': '2014-01-09', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-07-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'PK profile of lesinurad from plasma and urine', 'timeFrame': 'Days 1 and 6 (Sequence 1) or Days 2 and 7 (Sequence 2)', 'description': 'Profile in terms of Cmax, Tmax, AUC, CL/F, t1/2\n\nCmax: maximum concentration; Tmax: time to reach max plasma concentration; AUC: area under the concentration-time curve; CL/F: total body clearance corrected for bioavailability; t1/2: apparent terminal half-life'}], 'secondaryOutcomes': [{'measure': 'Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters', 'timeFrame': '6 weeks'}, {'measure': 'PD profile of lesinurad from serum', 'timeFrame': 'Days 1 and 6 (Sequence 1) or Days 2 and 7 (Sequence 2)', 'description': 'Profile in terms of serum urate concentration'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Healthy']}, 'descriptionModule': {'briefSummary': 'This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of ranitidine on lesinurad.', 'detailedDescription': 'This study will evaluate the potential effect of ranitidine on the pharmacokinetics of lesinurad. An earlier study demonstrated an effect on lesinurad PK in the presence of both calcium-containing and magnesium- and aluminum-containing antacids. The current study will assess whether raising gastric pH, without the presence of these cations, affects lesinurad PK and PD under the fasted state. If an impact is seen, then the optional second cohort will be conducted under the fed state.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* body weight ≥ 50 kg (110 lbs) and body mass index ≥ 18 and ≤ 30 kg/m2.\n* Screening sUA value ≤ 7.0 mg/dL.\n* free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures.\n* Subject has no clinically relevant abnormalties in vital signs, ECG, physical examination or safety laboratory values per the Investigator's judgment.\n\nExclusion Criteria:\n\n* history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic renal,urological, or psychiatric disorders.\n* history or suspicion of kidney stones.\n* undergone major surgery within 3 months prior to Day 1.\n* donated blood or experienced significant blood loss (\\> 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening visit.\n* inadequate venous access or unsuitable veins for repeated venipuncture."}, 'identificationModule': {'nctId': 'NCT01908257', 'briefTitle': 'Lesinurad Interaction Study With Ranitidine', 'organization': {'class': 'INDUSTRY', 'fullName': 'Ardea Biosciences, Inc.'}, 'officialTitle': 'A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects', 'orgStudyIdInfo': {'id': 'RDEA594-127'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Sequence 1 fasted', 'description': 'Day 1: Lesinurad 400 mg once daily (qd)\n\nDay 5: Ranitidine 150 mg twice daily (bid)\n\nDay 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.\n\nDay 7: Ranitidine 150 mg (bid)', 'interventionNames': ['Drug: lesinurad 400 mg', 'Drug: ranitidine 150 mg', 'Drug: lesinurad 400 mg + ranitidine 150 mg']}, {'type': 'EXPERIMENTAL', 'label': 'Sequence 2 fasted', 'description': 'Day 1: Ranitidine 150 mg (bid)\n\nDay 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad\n\nDay 3: Ranitidine 150 mg (bid)\n\nDay 7: Lesinurad 400 mg (qd)', 'interventionNames': ['Drug: lesinurad 400 mg', 'Drug: ranitidine 150 mg', 'Drug: lesinurad 400 mg + ranitidine 150 mg']}], 'interventions': [{'name': 'lesinurad 400 mg', 'type': 'DRUG', 'armGroupLabels': ['Sequence 1 fasted', 'Sequence 2 fasted']}, {'name': 'ranitidine 150 mg', 'type': 'DRUG', 'armGroupLabels': ['Sequence 1 fasted', 'Sequence 2 fasted']}, {'name': 'lesinurad 400 mg + ranitidine 150 mg', 'type': 'DRUG', 'armGroupLabels': ['Sequence 1 fasted', 'Sequence 2 fasted']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90630', 'city': 'Cypress', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 33.81696, 'lon': -118.03729}}], 'overallOfficials': [{'name': 'S. Bradley, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Ardea Biosciences, Inc.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ardea Biosciences, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}